» Articles » PMID: 36720562

Pattern of Oral Anticoagulant Prescribing for Atrial Fibrillation in General Practice: an Observational Study in The Netherlands

Overview
Journal BJGP Open
Specialty Public Health
Date 2023 Jan 31
PMID 36720562
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In the Dutch atrial fibrillation (AF) guideline for GPs, vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) are seen as equivalent, while in cardiology there is a preference for DOACs.

Aim: To describe the pattern of oral anticoagulant (OAC) prescribing for AF by GPs and assess whether GPs proactively convert between VKAs and DOACs in patients with AF.

Design & Setting: Observational study using routine practice data from 214 general practices, from 2017 until 2019.

Method: Patients aged ≥60 years diagnosed with AF, who had been prescribed OACs by their GPs in 2018 were included. A distinction was made between starters, who were participants who did not use OACs in 2017, and prevalent users. It was observed and recorded whether patients switched between VKAs and DOACs.

Results: A total of 12 516 patients with AF were included. Four hundred and seventy-six patients (4%) started OACs in 2018; 12 040 patients were prevalent OAC users. When GPs started patients on OACs, DOACs were prescribed the most (88%). Among prevalent users, more than half of the patients used VKAs (60%). GPs switched between OACs for 1% of starters and 0.6% of prevalent users in 2018 and 2019.

Conclusion: Dutch GPs predominantly start with DOACs in newly diagnosed patients with AF. Prevalent patients predominantly use VKAs and switching from a DOAC to a VKA is unusual. Consequently, the number of patients using VKAs will decline in the upcoming years. This trend raises questions about the future of organising frequent international normalised ratio (INR) checks for VKA users.

Citing Articles

Design and deployment of the STEEER-AF trial to evaluate and improve guideline adherence: a cluster-randomized trial by the European Society of Cardiology and European Heart Rhythm Association.

Sterlinski M, Bunting K, Boriani G, Boveda S, Guasch E, Mont L Europace. 2024; 26(7).

PMID: 38940494 PMC: 11289729. DOI: 10.1093/europace/euae178.

References
1.
Di Carlo A, Bellino L, Consoli D, Mori F, Zaninelli A, Baldereschi M . Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project. Europace. 2019; 21(10):1468-1475. DOI: 10.1093/europace/euz141. View

2.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38):2893-2962. DOI: 10.1093/eurheartj/ehw210. View

3.
Benzimra M, Bonnamour B, Duracinsky M, Lalanne C, Aubert J, Chassany O . Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation. Patient Prefer Adherence. 2018; 12:79-87. PMC: 5757966. DOI: 10.2147/PPA.S131158. View

4.
Eikelboom J, Connolly S, Brueckmann M, Granger C, Kappetein A, Mack M . Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369(13):1206-14. DOI: 10.1056/NEJMoa1300615. View

5.
Kuchinke W, Ohmann C, Verheij R, Van Veen E, Arvanitis T, Taweel A . A standardised graphic method for describing data privacy frameworks in primary care research using a flexible zone model. Int J Med Inform. 2014; 83(12):941-57. DOI: 10.1016/j.ijmedinf.2014.08.009. View